Genmab — Januar 2021
-
Genmab's neighbour Merus NV Announce Collaboration with Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. https://ir.merus.nl/news-releases/news-release-details/lilly-and-merus-nv-announce-collaboration-discover-novel-t-cell
-
-
https://www.jnj.com/janssen-submits-application-to-u-s-fda-seeking-approval-of-amivantamab-for-the-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations
Nej, der er vist ikke RTOR på Amivantamab. Det var en fejl fra min side. Her JNJs pm -
Nej, på ph1 studie ved navn CHRYSALIS
-
hvad forventer vi den 26/1 mht Kesimpta?? Er der nogen ide om, hvor højt salget er
?? -
for q4
-
Er Novartis begyndt kræve betaling?
-
27/10 12:57
af E L
To provide access to eligible US patients while they obtain reimbursement we are providing Kesimpta free of charge for a limited amount of time. Based on our assumption on the time from initiation of therapy to reimbursement we anticipate that a majority of the sales in the first quarter of launch will be free goods and have accrued accordingly. We expect this share to decrease over time as reimbursement progresses -
ok thx
-
God morgen.
-
Onsdagens aviser med Joe Biden, hjemmearbejde og aktieboblehttps://www.proinvestor.com/investornyt/671262/onsdagens-aviser-med-joe-biden-hjemmearbejde-og-aktieboble
-
Jep - jeg forventer at vi ser en stigning m/m på intet mindre end 20%
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind